HR+/HER2- breast cancer involves cells that test positive for hormone receptors and negative for HER2 proteins. It's the most ...

AstraZeneca has reported positive outcomes from a planned interim analysis of the double-blind Phase III SERENA-6 trial of ...

A first-of-its-kind antiviral gel may offer the potential to stop papillomavirus (HPV) infection before it causes cancer. ( ...

In the Phase III SERENA-6 trial, camizestrant—in combination with CDK-inhibitors—beat out current standard-of-care treatments ...

Metronomic capecitabine plus an aromatase inhibitor improved survival outcomes in hormone receptor-positive, HER2-negative ...

AstraZeneca (AZN) and Daiichi Sankyo’s (DSNKY) trastuzumab deruxtecan has been recommended for approval in the European Union as a monotherapy ...

Daiichi Sankyo and AstraZeneca’s Enhertu has been recommended for approval in the European Union as a monotherapy for the treatment of adult patients with unresectable or metast ...

AstraZeneca's experimental breast cancer drug camizestrant, when combined with a cyclin-dependent kinase inhibitor, has shown significant improvement in delaying disease progression in patients with ...

Bank of America analysts estimate a peak sales potential of $6 billion for camizestrant across the SERENA-6 and SERENA-4 ...

Regarding patients with HER2-negative, estrogen receptor (ER)-positive breast cancer, the phase 3 KEYNOTE-756 study is ...

Eisai will maintain the rights to tasurgratinib worldwide outside of the licensed regions.

Positive high-level results from a planned interim analysis of the SERENA-6 Phase III trial showed that AstraZeneca’s ...